Get the Stockscreener App
1.70
2.86%
-0.05
After Hours:
1.73
0.03
+1.76%
Allarity Therapeutics Inc stock is traded at $1.70, with a volume of 276.49K.
It is down -2.86% in the last 24 hours and down -9.57% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
See More
Previous Close:
$1.75
Open:
$1.72
24h Volume:
276.49K
Relative Volume:
0.04
Market Cap:
$24.85M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00825
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+4.94%
1M Performance:
-9.57%
6M Performance:
+126.33%
1Y Performance:
+6.25%
1-Day Range:
$1.66
$1.7401
1-Week Range:
$1.53
$1.77
52-Week Range:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.70 | 25.42M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Is Allarity Therapeutics Inc. stock a smart buy before Fed meetingAnalyst Downgrade & Expert Curated Trade Ideas - newser.com
Can technical indicators confirm Allarity Therapeutics Inc.’s reversalIndex Update & Free Growth Oriented Trading Recommendations - newser.com
Using data tools to time your Allarity Therapeutics Inc. exitQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
What drives Allarity Therapeutics Inc stock priceMid Cap Growth Trends & Access Free Risk Analysis Before You Invest - earlytimes.in
Is a relief rally coming for Allarity Therapeutics Inc. holdersEarnings Beat & Technical Buy Zone Confirmation - newser.com
What Wall Street predicts for Allarity Therapeutics Inc. stock priceJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
What MACD and RSI say about Allarity Therapeutics Inc.2025 Dividend Review & Weekly Market Pulse Updates - newser.com
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Decrease in Short Interest - Defense World
Is Allarity Therapeutics Inc a good long term investmentMACD Histogram Signals & Superior Capital Trading Plans - Early Times
Published on: 2025-09-27 05:03:48 - newser.com
Ascendiant Capital Markets Issues Positive Forecast for Allarity Therapeutics (NASDAQ:ALLR) Stock Price - Defense World
Ascendiant Capital Maintains Allarity Therapeutics (ALLR) Buy Recommendation - Nasdaq
Allarity Therapeutics (ALLR): Ascendiant Capital Raises Price Ta - GuruFocus
Allarity Therapeutics registers 1.56M shares for resale - MSN
Allarity Therapeutics Secures $2.5M Through Private Placement - MSN
Allarity presents new Phase 2 clinical data for Stenoparib - TipRanks
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - The Manila Times
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
25+ Month Survival Milestone: Allarity's New Cancer Drug Outperforms Standard Therapy by 9 Months in Trial - Stock Titan
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):